Showing 1931-1940 of 5643 results for "".
- Report: Dry Eye Treatment Devices Market Size Worth $400.8 Million By 2027https://modernod.com/news/report-dry-eye-treatment-devices-market-size-worth-400-8-million-by-2027/2478591/The global dry eye treatment devices market size is estimated to reach US$400.8 million by 2027, expanding at a CAGR of 6.4%, according to a new report by Grand View Research, Inc. The increasing demand for targeted, noninvasive, faster, and patient compliant treatment methods to alleviate dry ey
- NovaBay Pharmaceuticals Expands Avenova’s Geographic Reach to Australia with New Exclusive Distribution Agreementhttps://modernod.com/news/novabay-pharmaceuticals-expands-avenovas-geographic-reach-to-australia-with-new-exclusive-distribution-agreement/2478586/NovaBay Pharmaceuticals announced the signing of an agreement with Paragon Care Group Australia Pty for the exclusive distribution of Avenova in Australia. Paragon Care Group will begin distributing Avenova directly to consumers under its Designs For Vision brand beginning in early 2021. “
- Azar Expects 40M COVID-19 Vaccine Doses Ready to Distribute By End of Decemberhttps://modernod.com/news/azar-expects-40m-covid-19-vaccine-doses-ready-to-distribute-by-end-of-december/2478576/Department of Health and Human Services Secretary Alex Azar expects 40 million doses of Pfizer and Moderna’s COVID-19 vaccines will be ready for distribution by the end of December as providers must gear up now to allocate the doses, according to a FierceHealthcare
- Hydrus Microstent Receives Highest Designation of Any MIGS Device as Part of AAO Treatment Guidelineshttps://modernod.com/news/hydrus-microstent-receives-highest-designation-of-any-migs-device-as-part-of-aao-treatment-guidelines/2478570/Ivantis, developer of the novel Hydrus Microstent MIGS device, announced that the American Academy of Ophthalmology (AAO) has designated the Hydrus Microstent as “Level 1, Moderate Quality, Strong Recommendation.” The designation is the highest of any MIGS device in its 2020 Preferred Practice Pa
- iSTAR Medical’s Glaucoma Device MINIject Shows Positive One-Year Results in European Trialhttps://modernod.com/news/istar-medicals-glaucoma-device-miniject-shows-positive-one-year-results-in-european-trial/2478552/iSTAR Medical announced positive 1-year results from the European STAR-II clinical trial of its micro-invasive glaucoma surgery (MIGS) device, MINIject. The results have been presented at the virtual American Academy of Ophthalmology (AAO) annual meeting, held November 13-15 2020. Po
- FDA Fast-Tracks Novavax COVID-19 Vaccine NVXCoV2373https://modernod.com/news/fda-fast-tracks-novavax-covid-19-vaccine-nvxcov2373/2478517/Novavax said Monday that its experimental COVID-19 vaccine NVX-CoV2373 has received fast-track designation from the FDA. The company also reiterated that it expects to begin a pivotal phase 3 trial of the candidate in the US and Mexico by the end of November, data from which could be used to supp
- Avellino Introduces Multiplex Respiratory Panel for Simultaneous Detection of COVID-19 and Influenzahttps://modernod.com/news/avellino-introduces-multiplex-respiratory-panel-for-simultaneous-detection-of-covid-19-and-influenza/2478505/Avellino announced that the company has developed a novel multi-panel RT-PCR-based virus assay, AvellinoCoV2-Respiratory, which has been validated following the FDA’s Policy for Diagnostics Testing in Laboratories Certified to Perform High-Complexity Testing CLIA guidelines. The AvellinoCoV
- Novartis Acquires Vedere Bio, Adding Novel Optogenetic Gene Therapy Technology for Treating Blindnesshttps://modernod.com/news/novartis-acquires-vedere-bio-adding-novel-optogenetic-gene-therapy-technology-for-treating-blindness/2478474/Novartis announced that it has acquired Vedere Bio, adding a new platform for AAV-based delivery of gene therapies and an optogenetics program. The acquisition will enable Novartis to advance its efforts to bring transformative therapies to a wide range of patients with blinding diseases.
- Concerns Over Surgical Waste Are Clouding Future of Single-Use Device Markethttps://modernod.com/news/concerns-over-surgical-waste-are-clouding-future-of-single-use-device-market/2478423/The global single-use surgical device market has shown steady growth over several decades, reaching a peak of $3.4 billion in 2019, but growing concerns over the amount of waste created by disposable surgical devices have raised questions about future growth prospects, according to a Market Scope
- Tarsus Releases Data from Io and Europa Trials for TP-03 to Treat Demodex Blepharitis and Begins Phase 2b/3 Saturn-1 Trialhttps://modernod.com/news/tarsus-releases-data-from-io-and-europa-trials-for-tp-03-to-treat-demodex-blepharitis-and-begins-phase-2b-3-saturn-1-trial/2478374/Tarsus Pharmaceuticals announced data from its phase 2 trials, Io (a Phase 2a, single-arm open-label trial) and Europa (a Phase 2b, randomized vehicle-controlled trial), evaluating the safety and efficacy of TP-03, a novel ophthalmic therapeutic being developed for t